- Home
- AIRG vs KLRS Comparison
AIRG vs KLRS Comparison
Compare AIRG & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIRG
- KLRS
- Stock Information
- Founded
- AIRG 1995
- KLRS 2019
- Country
- AIRG United States
- KLRS United States
- Employees
- AIRG N/A
- KLRS N/A
- Industry
- AIRG Radio And Television Broadcasting And Communications Equipment
- KLRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AIRG Technology
- KLRS Health Care
- Exchange
- AIRG Nasdaq
- KLRS Nasdaq
- Market Cap
- AIRG 48.7M
- KLRS 46.0M
- IPO Year
- AIRG 2016
- KLRS N/A
- Fundamental
- Price
- AIRG $4.11
- KLRS $3.89
- Analyst Decision
- AIRG Strong Buy
- KLRS Strong Buy
- Analyst Count
- AIRG 3
- KLRS 2
- Target Price
- AIRG $8.50
- KLRS $23.00
- AVG Volume (30 Days)
- AIRG 26.7K
- KLRS 689.3K
- Earning Date
- AIRG 11-11-2025
- KLRS 08-13-2025
- Dividend Yield
- AIRG N/A
- KLRS N/A
- EPS Growth
- AIRG N/A
- KLRS N/A
- EPS
- AIRG N/A
- KLRS N/A
- Revenue
- AIRG $56,820,000.00
- KLRS N/A
- Revenue This Year
- AIRG N/A
- KLRS N/A
- Revenue Next Year
- AIRG $21.58
- KLRS N/A
- P/E Ratio
- AIRG N/A
- KLRS N/A
- Revenue Growth
- AIRG 6.84
- KLRS N/A
- 52 Week Low
- AIRG $3.17
- KLRS $2.14
- 52 Week High
- AIRG $10.34
- KLRS $24.15
- Technical
- Relative Strength Index (RSI)
- AIRG 39.86
- KLRS 57.01
- Support Level
- AIRG $4.10
- KLRS $2.37
- Resistance Level
- AIRG $4.40
- KLRS $4.90
- Average True Range (ATR)
- AIRG 0.20
- KLRS 0.67
- MACD
- AIRG -0.01
- KLRS 0.04
- Stochastic Oscillator
- AIRG 11.36
- KLRS 29.20
About AIRG Airgain Inc.
Airgain Inc is engaged in providing antenna technologies. These technologies can be used to enable performance wireless networking across devices and markets which include connected homes, enterprises, automotive, and the Internet of Things. It also provides solutions to complex radio frequency, engineering challenges, and improving wireless service that require higher throughput, broad coverage footprint, and carrier-grade quality. Geographically, it derives maximum revenue from North America and also has a presence in China and the Rest of the World. The company products include Antenna Plus: Fleet, M2M, IoT Antennas, Carrier-Class Antenna, Embedded Antennas, and External Dipole Antennas.
About KLRS Kalaris Therapeutics Inc. Common Stock
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.